-
'Where is she?' The desperate search for Venezuela's missing
-
Former Barca teen star Fati seals permanent Monaco switch
-
No business as usual after shock World Cup exit, say German FA
-
German rail regulator backs Italian firm in competition spat
-
Pope appeals to Catholic traditionalists to avoid schism
-
Ancelotti shows Brazil his worth at World Cup but concerns remain
-
US Supreme Court upholds transgender sports bans
-
Stocks rise, yen at 40-year low against dollar
-
US Supreme Court rejects Trump bid to restrict birthright citizenship
-
Australia hold West Indies to 125-7 in World Cup semi-final
-
Serena set for remarkable Wimbledon return, Swiatek survives scare
-
Defending champ Swiatek survives scare to reach Wimbledon second round
-
Africa EV firm Spiro accused of torturing Uganda employees
-
US Supreme Court upholds state bans on transgender athletes in school
-
PSG's Portugal forward Ramos signs five-year AC Milan deal
-
Tourists soldier on in Rome despite heatwave
-
Inflation slows in top eurozone economies as ECB ponders next move
-
Record number of 'new millionaires' in 2025, says UBS
-
Starmer boosts budget to modernise UK military before exit
-
UN calls for food, shelter to help Venezuela quake survivors
-
Stocks mostly higher, yen stays near 40-year low against dollar
-
Merz faces mockery over praise of Germany's World Cup team
-
Data centres emitting more CO2 than thought: study
-
Ride-share group BlaBlaCar taps AI for 20-country expansion
-
Over 1 million migrants apply for Spain's mass regularisation
-
Escaping heat, forgetting war: Kyiv locals hit the beach
-
Germany questions footballing identity after fresh World Cup failure
-
Thousands march to demand illegal migrants leave South Africa
-
MEXC Lists Ondo's Tokenized Strategy Preferred Stock on Spot Market
-
Serena set for remarkable Wimbledon return
-
Stocks climb, yen stays near 40-year low against dollar
-
Outgoing UK PM Starmer announces 'record' defence spending
-
Swim star Marchand limps out of French nationals as Europeans loom
-
Paralluelo joins Barca women's departures
-
UN says transport infrastructure must adapt to climate
-
Police hunt for Monaco bomb suspect after Ukrainian-born businessman wounded
-
Sommer, Acerbi, Darmian, De Vrij leave Inter Milan
-
Sommer, Acerbi, Darmian leave Inter Milan
-
Germany's labour market dilemma: rising unemployment despite vacancies
-
'Waiting like torture': Turks despair as Schengen visa delays mount
-
Skating allows Russian, Belarussians to return as neutrals
-
Venezuela rescuers in final push to find survivors as families mourn
-
Russian double Olympic figure skating champion Dmitriev dies aged 58
-
Over 1 million migrants apply for Spain's mass regularisation: PM
-
S. Africa deploys police as anti-migrant protests loom
-
Thousands from Philippine sect protest pro-Duterte senator's graft case
-
Monaco parcel bomb blast wounds Ukrainian oligarch
-
South Africa repatriations top 25,000 ahead of anti-immigrant ultimatum
-
Sweden face France's attacking firepower at the World Cup
-
Taiwan raids tech firms in China AI chip smuggling probe
US approves first at-home cervical cancer screening device
The US Food and Drug Administration has approved an at-home cervical cancer screening tool as an alternative to Pap smears by a gynecologist, the company behind the device said Friday.
The "Teal Wand" -- a self-collection vaginal swab shaped like a tampon and developed by Teal Health -- will be available online for individuals aged 25 to 65 who are at average risk for cervical cancer.
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
Cervical cancer, which affects the lower part of the uterus, is diagnosed in about 0.6 percent of women. Although HPV vaccination and regular screening are highly effective at preventing the disease, more than one in four women fall behind on routine appointments.
"When we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day," Teal Health CEO Kara Egan said in a statement.
The Teal Wand tests for high-risk strains of human papillomavirus (HPV), the primary cause of cervical cancer.
A large clinical trial found its accuracy comparable to a traditional Pap smear, which requires a speculum and is often cited as a barrier to screening due to discomfort.
Most sexually active people will contract HPV at some point, though only a small fraction develop cancer.
Teal Health did not disclose pricing but said it is in talks with insurers to ensure affordability. The product will launch first in California in June.
H.Seidel--BTB